Skip to content

Clinical Application of tDCS in Alzheimers Disease

Transcranial Direct Current Stimulation (tDCS) in Alzheimerâ??s Dementia (NEUROMOD-AD) Study: Efficacy and Follow up study of neuromodulation on Cognition and BPSD - Neuromod AD

Status
Active, not recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/08/056430
Enrollment
100
Registered
2023-08-11
Start date
Unknown
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F028- Dementia in other diseases classified elsewhere

Interventions

Intervention1: Transcranial Direct Current Stimulation: The active tDCS will involve 30-minutes of direct current at the intensity of 2 milliamperes (mA) area of the dorsolateral prefrontal cortex, ap

Sponsors

Department of Health Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Alzheimer disease diagnosed with NINDCS or DSM 5 criteria with MMSE score more than 16

Exclusion criteria

Exclusion criteria: 1.Participants with unstable medical conditions, serious metabolic and/or cardiac diseases, alcoholism, focal neurological disorders (e.g., epilepsy, stroke, brain injury or tumor) and associated psychiatric disorders 2.Using hypnotics and benzodiazepines up to 2 weeks before the start of the study 3.With any condition (e.g., communication, sensory, or motor deficits) that could significantly interfere with the neuropsychological assessment 4.Exclusion criteria relating to contraindications of neurostimulation will be applied, following the safety guidelines: (a) using psychoactive drugs (b) having implanted metallic or electronic devices; (c) having a cardiac pacemaker, seizures, acute eczema under the electrodes; and (d) the presence of tumors, epilepsy, or substance abuse

Design outcomes

Primary

MeasureTime frame
Global Cognitive PerformanceTimepoint: 1,2,4,12 weeks

Secondary

MeasureTime frame
Depressive SymptomsTimepoint: 1,2,4,8 weeks;Multi Domain dysfunctionTimepoint: 1,2,4,8 weeks;Quality of LifeTimepoint: 0,8 weeks;Zarit Burden InterviewTimepoint: 0,12 weeks

Countries

India

Contacts

Public ContactManushree Gupta

VMMC Safdarjung Hospital

manushree@gmail.com09711195900

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026